vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and INTERFACE INC (TILE). Click either name above to swap in a different company.
INTERFACE INC is the larger business by last-quarter revenue ($349.4M vs $180.9M, roughly 1.9× AVANOS MEDICAL, INC.). INTERFACE INC runs the higher net margin — 7.0% vs -0.7%, a 7.7% gap on every dollar of revenue. On growth, INTERFACE INC posted the faster year-over-year revenue change (4.3% vs 0.7%). INTERFACE INC produced more free cash flow last quarter ($28.6M vs $21.3M). Over the past eight quarters, INTERFACE INC's revenue compounded faster (9.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Interface, Inc., headquartered in Atlanta, Georgia, is a global manufacturer of commercial flooring. The company sells modular carpet tiles, luxury vinyl tile, and Nora brand rubber flooring.
AVNS vs TILE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $349.4M |
| Net Profit | $-1.3M | $24.4M |
| Gross Margin | 47.5% | 38.6% |
| Operating Margin | 1.4% | 10.1% |
| Net Margin | -0.7% | 7.0% |
| Revenue YoY | 0.7% | 4.3% |
| Net Profit YoY | 99.7% | 12.1% |
| EPS (diluted) | $-0.02 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $349.4M | ||
| Q3 25 | $177.8M | $364.5M | ||
| Q2 25 | $175.0M | $375.5M | ||
| Q1 25 | $167.5M | $297.4M | ||
| Q4 24 | $179.6M | $335.0M | ||
| Q3 24 | $170.4M | $344.3M | ||
| Q2 24 | $171.7M | $346.6M | ||
| Q1 24 | $166.1M | $289.7M |
| Q4 25 | $-1.3M | $24.4M | ||
| Q3 25 | $-1.4M | $46.1M | ||
| Q2 25 | $-76.8M | $32.6M | ||
| Q1 25 | $6.6M | $13.0M | ||
| Q4 24 | $-397.3M | $21.8M | ||
| Q3 24 | $4.3M | $28.4M | ||
| Q2 24 | $1.8M | $22.6M | ||
| Q1 24 | $-900.0K | $14.2M |
| Q4 25 | 47.5% | 38.6% | ||
| Q3 25 | 48.4% | 39.4% | ||
| Q2 25 | 52.6% | 39.4% | ||
| Q1 25 | 53.6% | 37.3% | ||
| Q4 24 | 54.6% | 36.5% | ||
| Q3 24 | 54.5% | 37.1% | ||
| Q2 24 | 55.7% | 35.4% | ||
| Q1 24 | 57.1% | 38.1% |
| Q4 25 | 1.4% | 10.1% | ||
| Q3 25 | 0.1% | 14.6% | ||
| Q2 25 | -42.6% | 13.9% | ||
| Q1 25 | 6.1% | 7.8% | ||
| Q4 24 | -233.0% | 8.8% | ||
| Q3 24 | 7.0% | 12.3% | ||
| Q2 24 | 3.7% | 11.0% | ||
| Q1 24 | 2.4% | 8.4% |
| Q4 25 | -0.7% | 7.0% | ||
| Q3 25 | -0.8% | 12.7% | ||
| Q2 25 | -43.9% | 8.7% | ||
| Q1 25 | 3.9% | 4.4% | ||
| Q4 24 | -221.2% | 6.5% | ||
| Q3 24 | 2.5% | 8.3% | ||
| Q2 24 | 1.0% | 6.5% | ||
| Q1 24 | -0.5% | 4.9% |
| Q4 25 | $-0.02 | $0.41 | ||
| Q3 25 | $-0.03 | $0.78 | ||
| Q2 25 | $-1.66 | $0.55 | ||
| Q1 25 | $0.14 | $0.22 | ||
| Q4 24 | $-8.64 | $0.38 | ||
| Q3 24 | $0.09 | $0.48 | ||
| Q2 24 | $0.04 | $0.38 | ||
| Q1 24 | $-0.02 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $71.3M |
| Total DebtLower is stronger | $90.3M | $181.6M |
| Stockholders' EquityBook value | $778.2M | $640.7M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.12× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $71.3M | ||
| Q3 25 | $70.5M | $187.4M | ||
| Q2 25 | $90.3M | $121.7M | ||
| Q1 25 | $97.0M | $97.8M | ||
| Q4 24 | $107.7M | $99.2M | ||
| Q3 24 | $89.0M | $115.6M | ||
| Q2 24 | $92.2M | $94.2M | ||
| Q1 24 | $75.8M | $89.8M |
| Q4 25 | $90.3M | $181.6M | ||
| Q3 25 | $93.4M | $307.8M | ||
| Q2 25 | $95.7M | $304.4M | ||
| Q1 25 | $98.0M | $302.9M | ||
| Q4 24 | $125.3M | $302.8M | ||
| Q3 24 | $152.6M | $337.9M | ||
| Q2 24 | $164.9M | $387.6M | ||
| Q1 24 | $167.2M | $391.8M |
| Q4 25 | $778.2M | $640.7M | ||
| Q3 25 | $778.0M | $621.0M | ||
| Q2 25 | $776.3M | $575.0M | ||
| Q1 25 | $839.4M | $513.1M | ||
| Q4 24 | $828.5M | $489.1M | ||
| Q3 24 | $1.2B | $501.6M | ||
| Q2 24 | $1.2B | $451.2M | ||
| Q1 24 | $1.2B | $428.5M |
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
| Q4 25 | 0.12× | 0.28× | ||
| Q3 25 | 0.12× | 0.50× | ||
| Q2 25 | 0.12× | 0.53× | ||
| Q1 25 | 0.12× | 0.59× | ||
| Q4 24 | 0.15× | 0.62× | ||
| Q3 24 | 0.12× | 0.67× | ||
| Q2 24 | 0.13× | 0.86× | ||
| Q1 24 | 0.14× | 0.91× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $49.3M |
| Free Cash FlowOCF − Capex | $21.3M | $28.6M |
| FCF MarginFCF / Revenue | 11.8% | 8.2% |
| Capex IntensityCapex / Revenue | 3.8% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 2.02× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $121.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $49.3M | ||
| Q3 25 | $14.0M | $76.7M | ||
| Q2 25 | $6.8M | $30.1M | ||
| Q1 25 | $25.7M | $11.7M | ||
| Q4 24 | $57.9M | $38.0M | ||
| Q3 24 | $23.0M | $76.2M | ||
| Q2 24 | $27.8M | $21.5M | ||
| Q1 24 | $-8.0M | $12.6M |
| Q4 25 | $21.3M | $28.6M | ||
| Q3 25 | $7.0M | $66.1M | ||
| Q2 25 | $-4.2M | $22.8M | ||
| Q1 25 | $19.0M | $4.3M | ||
| Q4 24 | $53.1M | $24.4M | ||
| Q3 24 | $20.0M | $69.7M | ||
| Q2 24 | $21.9M | $12.0M | ||
| Q1 24 | $-12.1M | $8.6M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 3.9% | 18.1% | ||
| Q2 25 | -2.4% | 6.1% | ||
| Q1 25 | 11.3% | 1.4% | ||
| Q4 24 | 29.6% | 7.3% | ||
| Q3 24 | 11.7% | 20.3% | ||
| Q2 24 | 12.8% | 3.5% | ||
| Q1 24 | -7.3% | 3.0% |
| Q4 25 | 3.8% | 5.9% | ||
| Q3 25 | 3.9% | 2.9% | ||
| Q2 25 | 6.3% | 2.0% | ||
| Q1 25 | 4.0% | 2.5% | ||
| Q4 24 | 2.7% | 4.1% | ||
| Q3 24 | 1.8% | 1.9% | ||
| Q2 24 | 3.4% | 2.8% | ||
| Q1 24 | 2.5% | 1.4% |
| Q4 25 | — | 2.02× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.93× | ||
| Q1 25 | 3.89× | 0.90× | ||
| Q4 24 | — | 1.75× | ||
| Q3 24 | 5.35× | 2.68× | ||
| Q2 24 | 15.44× | 0.95× | ||
| Q1 24 | — | 0.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
TILE
| AMS | $205.9M | 59% |
| EAAA | $143.5M | 41% |
